Navigation Links
Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
Date:9/30/2010

SAN DIEGO, Sept. 30 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has engaged Fabiani & Company to assist in the establishment of federal partnerships that advance biodefense, cancer, and chronic infectious disease applications of the Aethlon Hemopurifier®. The Aethlon Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. Fabiani & Company is a Washington, D.C.-based government affairs firm founded with the primary goal of providing a select group of clients creative and innovative strategies to effectively represent them and their interests before the United States Federal Government.

(Photo:  http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

(Photo:  http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

"Our colleagues at Fabiani & Company provide us a well respected presence inside the beltway and increase our likelihood of accessing non-dilutive resources to advance our endeavors across multiple disease conditions in the United States," stated Aethlon Chairman and CEO, Jim Joyce.  

"We are pleased and excited to partner with Aethlon Medical," said Fabiani & Company principal, Stephen Conafay. "Aethlon's experienced management team, coupled with their breakthrough Hemopurifier® technology offers to provide a wide variety of cancer and immune suppressed patients a minimally invasive therapeutic strategy at significantly reduced costs when compared to present therapies." Additional details can be accesse
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Aethlon Medical Reestablishes Biodefense Programs
2. Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
3. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
4. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
5. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
6. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
7. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
8. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
9. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
10. Millstone Medical Outsourcing Makes Strategic Hires in Memphis
11. Open Door Family Medical Centers Named Top Community Health Center in Nation for Use of Information Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013  BioRestorative Therapies, Inc. ("BRT" or the ... on developing stem cell based therapies for various personal ... its President and CEO, will be presenting at the ... be held on Thursday, May 30, 2013 at the ... in New York City.  Mr. Weinreb,s presentation will take ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, ... secondary analysis of its double-blind, randomized, controlled Phase ... a gene therapy product designed to deliver the ... analysis identified a more robust response to CERE-120 ... to treatment relative to those diagnosed 10 years ...
(Date:5/21/2013)... MONROVIA, Calif. , May 21, 2013 ... leading developer, manufacturer and marketer of minimally invasive ophthalmic ... upcoming investor conferences to review the Company,s recent financial ... STAAR Surgical will present at the 38 ... Boston at the Westin Waterfront ...
Breaking Medicine Technology:BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5STAAR Surgical To Present At Upcoming Investor Conferences 2
... COLLEGEVILLE, Pa., and TARRYTOWN, N.Y., May 22 ... ), and Progenics,Pharmaceuticals, Inc. (Nasdaq: PGNX ), ... with investigational oral and,intravenous formulations of RELISTOR(TM) (methylnaltrexone ... phase 2 trial, evaluated the effects of,an oral ...
... LAS VEGAS, May 22 CardioVascular,BioTherapeutics, Inc. (OTC Bulletin ... Christopher Moore to be the sponsor and general,partner of ... of,$1 million and up to $10 million of the ... am extremely impressed with CVBT,s wound healing drug, which ...
Cached Medicine Technology:Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 2Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 3Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 4Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 5Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 6Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 7Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 2Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 3
(Date:5/21/2013)... Spring is the perfect time to ... filled with whole foods to weather perfect for outdoor ... season the nutrition experts at Brilliant Nutrition highlight five ... , 1. Eating Locally, With the abundance of fresh ... and explore, spring is a great time to take ...
(Date:5/21/2013)... Feed additives have now become an ... chain. Most of the feed additives are used in ... and powders. There are variety of feed additives available ... upon the type of animal and feed. Nutritional feed ... essential nutrition to the animal in order to gain ...
(Date:5/21/2013)... Daily Gossip Magazine published well-documented articles that are ... people informed on the latest weight loss methods by publishing ... in-depth review of Kyle Leon’s Customized Fat ... want to lose weight or stay in shape with the ... was created by a popular fitness trainer, Kyle Leon, who ...
(Date:5/21/2013)... DISCcert has served the training industry for ... DISC applications at the July 25 & 26th ... July 25 & 26th DISC certification in San Diego, ... DISC. The time-tested, proven support materials will include valuable ... training materials ; worksheets, handouts, learning activities, power-points ...
(Date:5/21/2013)... 2013) Prostaglandin analogues (PGAs), drugs which lower intraocular ... people with glaucoma, but their use is not without ... dryness, changes in eye color and other side effects. ... also cause upper and lower eyelid drooping and other ... described in PLOS ONE . , Researchers from ...
Breaking Medicine News(10 mins):Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 2Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 3Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 3Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 4Health News:Customized Fat Loss Plan Review and Diet Secrets Revealed By Daily Gossip Magazine 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Glaucoma drug can cause droopy eyelids 2
... Inc. (Nasdaq: MSON ), a developer of ... is used for the ablation of tumors and worldwide ... has purchased three patents associated with High Intensity Focused ... relate to HIFU transducer arrays method of fabrication, ultrasonic ...
... with rheumatic diseases want more information and better communication ... their conditions, according to the results of a new ... of the European League Against Rheumatism in Copenhagen, Denmark. ... understand the importance of addressing sexual health with their ...
... Friday 12 June 2009: After five years of receiving ... spondylitis (AS) showed substantial clinical benefit (ASAS40, ASsessment in ... at five years, 78.4% of AS patients had no ... junction between tendon and bone). Over this period, patients ...
... CHICAGO, June 12 Germany ... by the eastern federal states.,This is in large part ... despite the economic crisis. American investor interest in,Germany remains ... Nordex AG shared their success stories at the "How,Far ...
... , Travelers Turn to InsureMyTrip.com for Coverage Protection and ... Stating ,the scientific criteria for an influenza pandemic have ... declared the A(H1N1) virus, commonly referred to as Swine ... http://www.newscom.com/cgi-bin/prnh/20070529/NETU076LOGO ) , , "Particularly ...
... 12 June 2009: 92.8% of patients with systemic lupus ... both their physical and emotional quality of life (QoL), ... today at EULAR 2009, the Annual Congress of the ... analysis revealed that depression was the most significant factor ...
Cached Medicine News:Health News:Misonix Announces the Purchase of Patents From ProRhythm, Inc. 2Health News:Misonix Announces the Purchase of Patents From ProRhythm, Inc. 3Health News:Better access to info and dialogue with HCPs on sexual issues for rheumatology patients 2Health News:Better access to info and dialogue with HCPs on sexual issues for rheumatology patients 3Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 2Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 3Health News:American Investors Highlight Successes in Eastern Germany 2Health News:World Health Organization Declares A(H1N1) Pandemic 2Health News:World Health Organization Declares A(H1N1) Pandemic 3Health News:Anxiety and depression lower quality of life in majority of systemic lupus erythematosus patients 2
... Adjustable Post-Operative Pin Knee Brace (POP) for ... associated with ACL, PCL, MCL, and LCL ... extension in 7 increments. Can be locked ... increases compliance. Breakaway hinge bar converts long ...
... The Aircast Patellar Brace is a ... unique "horseshoe" shaped aircell stabilizes the patella ... maintain the position of the patella. During ... helping to reduce swelling and pain. A ...
... Pediatric Knee/Elbow Cryo/Cuff is specifically designed to treat ... the therapeutic benefits of controlled compression to minimize ... Due to the unique design of the cuff, ... knee and elbow of the patient. The Pediatric ...
... therapeutic benefits of controlled compression to minimize hemarthrosis ... cuff is anatomically designed to completely fit the ... available in three sizes for adults and is ... children 1 - 7 years of age. A ...
Medicine Products: